Image Source: Pixabay
Novo Nordisk (NVO) is positioning its new obesity drug, CagriSema, to potentially lead to at least 25% weight loss in patients, setting a new benchmark in the competitive weight-loss drug market. This combination of semaglutide, which mimics the GLP-1 hormone, and cagrilintide, which targets another hormone, amylin, aims to provide enhanced efficacy without increased side effects. The company hopes to differentiate itself as it faces strong competition from Eli Lilly’s Zepbound, which has already demonstrated greater weight loss, and other upcoming therapies that may offer simpler dosing options.Video Length: 00:02:28More By This Author:Seasonal Opportunities In The Dax Will The Dollar Rise After The US Election? Remember, Remember The First Days Of November
